About Oncodesign
Oncodesign is a company based in Dijon (France) founded in 1995 was acquired by Edmond de Rothschild in October 2022. Oncodesign has raised $4.71 million across 1 funding round from investors including Edmond de Rothschild, Banque de Vizille and Avenir Entreprises. Oncodesign offers products and services including OncoSNIPER, Nanocyclix, and PROMETHE. Oncodesign operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Dijon, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.71 M (USD)
in 1 rounds
-
Latest Funding Round
$4.71 M (USD), Series A
May 22, 2008
-
Investors
Edmond de Rothschild
& 2 more
-
Employee Count
Not available
-
Acquired by
Edmond de Rothschild
(Oct 19, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oncodesign
Oncodesign offers a comprehensive portfolio of products and services, including OncoSNIPER, Nanocyclix, and PROMETHE.
Technology for targeting cancer resistance in precision medicine.
Platform developing novel compounds for oncology treatments.
Tool for advancing biopharmaceutical research and diagnostics.
People of Oncodesign
Unlock access to complete
Leadership Team
4 people
Creative and Marketing Team
1 people
Data Analysis and Operations Team
1 people
Unlock access to complete
Funding Insights of Oncodesign
Oncodesign has successfully raised a total of $4.71M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.71 million completed in May 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oncodesign
Oncodesign has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Edmond de Rothschild, Banque de Vizille and Avenir Entreprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Content on business, technology, and digital trends is provided.
|
Locked | Locked | Locked | |
|
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Oncodesign
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oncodesign
Investment portfolio details for Oncodesign
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oncodesign
Detailed financials for Oncodesign
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncodesign Comparisons
Peer comparison for Oncodesign
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oncodesign
Oncodesign operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Oncodesign
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncodesign
Complete news archive for Oncodesign
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncodesign
Oncodesign was founded in 1995 and raised its 1st funding round 13 years after it was founded.
Oncodesign is headquartered in Dijon, France. It is registered at Dijon, Bourgogne-franche-comte, France.
Oncodesign is a funded company, having raised a total of $4.71M across 1 funding round to date.
Oncodesign was founded in 1995 in Dijon, France, as an oncology-focused contract research organization. Preclinical evaluations of anti-cancer therapies are conducted using three main platforms: PREDICT for standard in vitro and in vivo pharmacology, Chi-Mice for humanized chimeric models in vivo, and PharmImage for non-invasive multimodal imaging. Additionally, Nanocyclix technology is applied in discovery processes to develop selective macrocyclic kinase inhibitors, supporting therapeutic assessments in the oncology sector.
Oncodesign's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Oncodesign offers OncoSNIPER, Nanocyclix, and PROMETHE.
Oncodesign has 3 investors. Key investors include Edmond de Rothschild, Banque de Vizille, and Avenir Entreprises.